Table 3. Estimated vaccination coverage with selected vaccines and vaccine series among children 19-35 months, by year and 

sampling frame, National Immunization Survey-Child, 2016-2017*

 2016 2017

Vaccine

Single†-Frame 

Estimate

Dual§-Frame 

Estimate Difference¶ Single-Frame Estimate

Dual-Frame 

Estimate Difference

% (95% CI) % (95% CI) Percentage 

Points (95% CI) % (95% CI) % (95% CI) Percentage Points (95% CI)

DTaP** 

≥3 doses 93.8 (92.8-94.8) 93.7 (92.9-94.5) -0.1 (-0.4-0.2) 94.1 (93.4-94.8) 94.0 (93.3-94.7) -0.1 (-0.4-0.2)

≥4 doses 83.8 (82.4-85.2) 83.4 (82.1-84.7) -0.4 (-0.9-0.1) 83.7 (82.5-84.9) 83.2 (82.0-84.4) -0.5 (-1.0-0.0)

Poliovirus (≥3 doses) 91.7 (90.4-93.0) 91.9 (90.9-92.9) 0.2 (-0.1-0.5) 92.6 (91.7-93.5) 92.7 (91.9-93.5) 0.1 (-0.2-0.4)

MMR (≥1 dose) †† 91.2 (90.1-92.3) 91.1 (90.1-92.1) -0.1 (-0.4-0.2) 91.3 (90.4-92.2) 91.5 (90.6-92.4) 0.1 (-0.2-0.4)

Hib§§

 Primary series 91.7 (90.6-92.8) 91.6 (90.7-92.5) -0.1 (-0.4-0.2) 91.8 (90.9-92.7) 91.8 (90.9-92.7) 0.0 (-0.3-0.3)

Full series 81.9 (80.5-83.3) 81.8 (80.5-83.1) 0.0 (-0.4-0.4) 81.0 (79.7-82.3) 80.7 (79.4-82.0) -0.3 (-0.8-0.2)

HepB

 ≥3 doses 90.4 (89.1-91.7) 90.5 (89.4-91.6) 0.1 (-0.3-0.5) 91.3 (90.3-92.3) 91.4 (90.5-92.3) 0.2 (-0.1-0.5)

Birth dose¶¶ 71.3 (69.5-73.1) 71.1 (69.5-72.7) -0.2 (-0.8-0.4) 73.5 (71.8-75.2) 73.6 (72.0-75.2) 0.1 (-0.5-0.7)

Varicella (≥1 dose)†† 90.9 (89.8-92.0) 90.6 (89.6-91.6) -0.2 (-0.5-0.1) 90.8 (89.8-91.8) 91.0 (90.1-91.9) 0.2 (-0.1-0.5)
††† Includes ≥2 doses of Rotarix monovalent rotavirus vaccine (RV1), or ≥3 doses of RotaTeq pentavalent rotavirus vaccine (RV5). The maximum age for the final rotavirus dose is 

 8 months, 0 days.

§§§The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 

 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of varicella vaccine, and ≥4 doses of PCV.

PCV

 ≥3 doses 92.0 (90.9-93.1) 91.8 (90.8-92.8) -0.1 (-0.4-0.2) 91.8 (90.8-92.8) 91.9 (90.9-92.9) 0.1 (-0.2-0.4)

 ≥4 doses

82.0 (80.5-83.5) 81.8 (80.5-83.1) -0.2 (-0.8-0.4) 82.8 (81.5-84.1) 82.4 (81.1-83.7) -0.4 (-0.8-0.0)

HepA

 ≥1 dose

86.1 (84.7-87.5) 86.1 (85.0-87.2) 0.0 (-0.4-0.4) 86.4 (85.3-87.5) 86.0 (84.9-87.1) -0.4 (-0.9-0.1)

 ≥2 doses***

61.3 (59.5-63.1) 60.6 (59.0-62.2) -0.6 (-1.2-0.0) 60.2 (58.5-61.9) 59.7 (58.1-61.3) -0.4 (-1.0-0.2)

Rotavirus†††

74.4 (72.7-76.1) 74.1 (72.6-75.6) -0.3 (-0.9-0.3) 73.6 (72.0-75.2) 73.2 (71.6-74.8) -0.4 (-1.0-0.2)

Combined 7-vaccine 

series§§§ 71.1 (69.4-72.8) 70.7 (69.2-72.2) -0.4 (-1.0-0.2) 70.4 (68.8-72.0) 70.4 (68.9-71.9) 0.1 (-0.5-0.7)

No vaccinations 0.7 (0.6-0.8) 0.8 (0.6-1.0) 0.1 (0.0- 0.2) 1.1 (0.9-1.3) 1.1 (0.9-1.3) 0.0 (-0.1-0.1)

Abbreviations: CI = confidence interval; DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; 

Hib = Haemophilus influenzae type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine.

* Data for the 2016 survey year include children born during January 2013–May 2015 and for 2017 include children born during January 2014–May 2016.

† Single-frame is defined as households with only cellphones 

§ Dual-frame is defined as households with both landlines and cell-phones. ¶ Difference between proportion of dual households and the proportion of single households.

** Includes children who may have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine †† Includes children who may have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.

§§ Hib primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending 

on product type received.

¶¶ One dose of HepB administered from birth through age 3 days. *** Estimates of ≥2 doses of HepA are likely underestimates because a child could be on schedule but not receive a second dose of HepA until age 41 months. This dose would not be

collected by NIS-Child, which includes children aged 19–35 months only.